Bristol-Myers Squibb: News
 
 
 
Partnering News
December 28, 2012Bristol-Myers Squibb and Pfizer Announce U.S. FDA Approval of ELIQUIS® (apixaban)December 26, 2012ELIQUIS® (apixaban) Approved In Japan For The Prevention Of Stroke And Systemic Embolism In Patients With Nonvalvular Atrial FibrillationDecember 12, 2012The Medicines Company and Bristol-Myers Squibb Agree to Global Alliance For Recothrom®December 9, 2012Elotuzumab Progression-Free Survival Data from Phase 2 Study of Patients with Previously-Treated Multiple Myeloma Presented at 54th American Society of Hematology (ASH) Annual MeetingDecember 8, 2012ELIQUIS® (apixaban) Demonstrated Superiority In Reducing A Composite Of Recurrent Venous Thromboembolism And All-Cause Death Without Increasing The Rate Of Major Bleeding Versus Placebo During One Year Of Extended TreatmentNovember 20, 2012ELIQUIS®(apixaban) Approved in Europe for Prevention of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial FibrillationNovember 2, 2012Bristol-Myers Squibb and Pfizer Announce New Data on Stroke Prevention in Atrial Fibrillation to be Presented at American Heart Association 2012 Scientific SessionsNovember 1, 2012Portola, Bristol-Myers Squibb and Pfizer Sign Clinical Collaboration Agreement to Study ELIQUIS® and Portola’s Universal Factor Xa Inhibitor Antidote PRT4445October 3, 2012Sanofi and Bristol-Myers Squibb Announce Restructuring of Alliance AgreementOctober 1, 2012ELIQUIS® (apixaban) Demonstrates Consistent Reductions in Stroke and Systemic Embolism, Major Bleeding and Mortality Compared to Warfarin in Patients with Nonvalvular Atrial Fibrillation at Varying Risk for Stroke and BleedingSeptember 21, 2012Vanderbilt University and Bristol-Myers Squibb Sign Collaboration Agreement to Develop Novel Treatments for Parkinson’s DiseaseSeptember 21, 2012ELIQUIS® (apixaban) Receives CHMP Positive Opinion For The Prevention Of Stroke And Systemic Embolism In Patients With Nonvalvular Atrial FibrillationAugust 9, 2012Bristol-Myers Squibb and AstraZeneca Complete Expansion of Diabetes Alliance Through Bristol-Myers Squibb’s Acquisition of AmylinAugust 9, 2012Bristol-Myers Squibb Completes Acquisition of Amylin Pharmaceuticals, Inc.June 29, 2012Bristol-Myers Squibb and AstraZeneca Expand Diabetes Alliance Through Bristol-Myers Squibb’s Acquisition of Amylin PharmaceuticalsJune 20, 2012Bristol-Myers Squibb and Emory University Announce Partnership to Advance Clinical Development of Investigational CompoundsMay 14, 2012Bristol-Myers Squibb and Tsinghua University Enter Strategic PartnershipMarch 28, 2012Bristol-Myers Squibb and Meso Scale Discovery Enter Agreement to Develop Diagnostic Assays for Alzheimer’s DiseaseFebruary 28, 2012Bristol-Myers Squibb and Duke Translational Medicine Institute Form Strategic Relationship to Broaden InteractionsFebruary 3, 2012Bristol-Myers Squibb Announces Expiration of the Hart-Scott-Rodino Waiting Period for Acquisition of Inhibitex, Inc.January 7, 2012Bristol-Myers Squibb to Acquire InhibitexDecember 22, 2011Bristol-Myers Squibb and the Gladstone Institutes Enter Three-Year Discovery Partnership in Alzheimer’s DiseaseDecember 13, 2011Simcere and Bristol-Myers Squibb Enter Innovative Partnership to Develop Cardiovascular CompoundDecember 2, 2011Bristol-Myers Squibb Enters Clinical Collaboration Agreement with Tibotec Pharmaceuticals for Phase II Combination Study in Patients Chronically Infected with Hepatitis CNovember 7, 2011FDA Approves ERBITUX® (cetuximab) for First-Line Recurrent Locoregional or Metastatic Head and Neck Cancer in Combination with Platinum-based Chemotherapy with 5-Fluorouracil
 
 
 
 


You are leaving BMS.com to go to the Amylin Job Search and application tool. IMPORTANT TO NOTE: This may require a separate login and password than what is used for the Bristol-Myers Squibb search and application process.